Treatment of patients with neuropathic pain and provision of drug information by clinical pharmacists
DOI:
https://doi.org/10.1590/Palavras-chave:
Neuropathic pain, Clinical pharmacist, Drug information, Patient satisfaction, Adjuvant analgesicsResumo
Patient’s satisfaction with healthcare services has an influence on pain management, which can be improved by patient education. Therefore, this study was aimed at identifying primary care health service opportunities in the treatment of neuropathic pain and assessing patients’ satisfaction with the provision of drug information by clinical pharmacists. This was a cross- sectional, prospective study conducted at a pain unit during March-May 2017. Patients aged >18 years; diagnosed with neuropathic pain; and who used amitriptyline, gabapentin, pregabalin, or duloxetine were included. They were verbally informed about drug treatment by a clinical pharmacist, and their satisfaction was evaluated after 1 month. In all, 90 patients were included. The median duration for which the patients experienced pain until hospital admission was 3.6 years; furthermore, this duration was longer among women (p < 0.05). However, the median time to seeking advice from doctors was 3 months. The patients (15.6%) were less likely to admit pain unit initially and 46.7% had visited different units before being admitted to a pain unit. More than 95% of the patients indicated that they had received information from a pharmacist at a clinic and were satisfied with the provision of information (median duration, 8.5 min). Thus, the involvement of pharmacists in multidisciplinary pain management may help improve health- related outcomes at hospitals and/or in community care settings.
Downloads
Referências
Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88.
Bennett MI, Bagnall AM, Raine G, Closs SJ, Blenkinsopp A, Dickman A, et al. Educational interventions by pharmacists to patients with chronic pain: systematic review and meta-analysis. Clin J Pain. 2011;27:623-30.
Blyth FM. Global burden of neuropathic pain. Pain. 2018;159:614-17.
Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain , 2008;136:380-7.
Coffey CP, Ulbrich TR, Baughman K, Awad MH. The effect of an interprofessional pain service on nonmalignant pain control. Am J Health Syst Pharm. 2019;76(supplement 2):S49-S54.
Cohen SP, Mao J. Neuropathic pain: mechanisms and their clinical implications. BMJ. 2014;348:f7656.
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002.
Dworkin RH, O’Connor AB, Kent J, Mackey SC, Raja SN, Stacey BR, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain . 2013;154(11):2249-61.
Edwards Z, Ziegler L, Craigs C, Blenkinsopp A, Bennett MI. Pharmacist educational interventions for cancer pain management: a systematic review and meta-analysis. Int J Pharm Pract. 2019;27(4):336-45.
Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162-73.
Garven A, Brady S, Wood S, Hatfield M, Bestard J, Korngut L, et al. The impact of enrollment in a specialized interdisciplinary neuropathic pain clinic. Pain Res Manag. 2011;16(3):159-68.
International Association for the Study of Pain. 2007. Pain in women. (visited on September 2019) Available from: Available from: https://www.iasp-pain.org/GlobalYear/PaininWomen
» https://www.iasp-pain.org/GlobalYear/PaininWomen
Jensen TS, Baron R, Haanpaa M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain . 2011;152(10):2204-5.
Jones LK, Lussier ME, Brar J, Byrne MC, Durham M, Kiokemeister F, et al. Current interventions to promote safe and appropriate pain management. Am J Health Syst Pharm . 2019;76(11):829-34.
Jonsdottir T, Jonsdottir H, Gunnarsdottir S, Lindal E. Health care utilization in chronic pain-A population based study. Scandinavian Journal of Pain. 2013;4(4):255-55.
Kamerman PR, Wadley AL, Davis KD, Hietaharju A, Jain P, Kopf A, et al. World Health Organization essential medicines lists: where are the drugs to treat neuropathic pain?. Pain . 2015;156(5):793-7.
Moulin DE, Clark AJ, Gordon A, Lynch M, Morley-Forster PK, Nathan H, et al. Long-term outcome of the management of chronic neuropathic pain: A prospective observational study. J Pain . 2015;16(9):852-61.
National Institute for Health and Care Excellence (NICE), 2019. Neuropathic pain in adults: pharmacologic management in non-specialist settings. Contract No.: CG173 (visited on September, 2019). Available from: Available from: https://www.nice.org.uk/guidance/cg173
» https://www.nice.org.uk/guidance/cg173
Navarro A, Saldana MT, Perez C, Torrades S, Rejas J. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings. BMC Neurol. 2011;11:7.
Nicholson B, Verma S. Comorbidities in chronic neuropathic pain. Pain Med. 2004;5(Suppl 1):S9-S27.
Romanelli, RJ, Shah SN, Ikeda L, Lynch B, Craig TL, Cappelleri JC, et al. Patient characteristics and healthcare utilization of a chronic pain population within an integrated healthcare system. Am J Manag Care. 2017;23(2):e50-e56.
Schaefer C, Sadosky A, Mann R, Daniel S, Parsons B, Tuchman M, et al. Pain severity and the economic burden of neuropathic pain in the United States: BEAT Neuropathic Pain Observational Study. Clinicoecon Outcomes Res. 2014;6:483-96.
Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community. Clin J Pain . 2007;23(2):143-9.
Tompkins DA, Hobelmann JG, Compton P. Providing chronic pain management in the “Fifth Vital Sign” Era: Historical and treatment perspectives on a modern-day medical dilemma. Drug Alcohol Depend. 2017;173(Suppl 1):S11-S21.
Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain . 2006;7(4):281-9.
Van Acker K, Bouhassira D, De Bacquer D, Weiss S, Matthys K, Raemen H, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35(3):206-13.
van Hecke O, Austin SK, Khan RA, Smith BH, Torrance N. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain . 2014;155(4):654-62.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2022 Brazilian Journal of Pharmaceutical Sciences
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.
